Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PROMPT-IBD: Early Infliximab Optimization
NCT06758024Recruiting
- Sponsor
- Pontificia Universidad Católica de Chile
- Start
- Jan 2025
- Primary completion
- Jan 2026
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised, open-label trial of infliximab in inflammatory bowel disease (IBD), Crohn's disease and ulcerative colitis (UC) (2 arms), sponsored by Pontificia Universidad Católica de Chile. Primary endpoint: Infliximab optimal concentration at 14 weeks. Started Jan 2025; status: recruiting.
02
Drugs
infliximab
03
Conditions
inflammatory bowel disease (IBD)Crohn's diseaseulcerative colitis (UC)
Beyond the preview
Go deeper on NCT06758024.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06758024.